Literature DB >> 9054901

A quantitative assessment of standard vs. customized midline shield construction for invasive cervical carcinoma.

A H Wolfson1, M Abdel-Wahab, A M Markoe, W J Raub, D Diaz, J J Desmond, J Y Ting.   

Abstract

PURPOSE: An individualized midline shield (MLS) has been advocated for delivering homogeneous radiotherapy for patients with invasive cervical carcinoma. Yet, many radiation oncologists continue to employ a standard block. In the latter instance, any deviation of the cranial-caudal central axis of he tandem from the patient's midline could result in dose inhomogeneity to tumor. A retrospective review of a single university medical center's experience with constructing the MLS was initiated to determine the outcome of using a standard block vs. a customized block that conforms to the "Point A" isodose line. In addition, participating radiation oncologists associated with the Gynecologic Oncology Group (GOG) were polled to assess if there exists a consensus regarding midline block utilization in the management of cervical cancer patients which could be compared to the institutional study. METHODS AND MATERIALS: From January 1, 1990 through December 31, 1992, 32 patients with invasive cervical carcinoma who underwent low dose rate brachytherapy at a single institution were identified. Patients were grouped as having a standard block (18 cases), customized block (5 cases), or no block (9 cases). The "Point A" isodose distribution from the implant was superimposed onto the whole pelvic simulation film and quantitatively compared to the actual or a hypothetical standard block outlined on the same radiograph. In September of 1995, 56 member and affiliated institutions in the GOG were surveyed concerning their use of a MLS, and the results were tabulated in December of 1995.
RESULTS: Approximately 72% of all cases (23 out of 32) at the single institution had tandem deviation ranging from 0-230 with a median of 50. This translated into a median percent overdosage to "Point A" Right of 15% and "Point A" Left of 12.5%. Although overall survival and incidence of chronic complications have not been affected by type of shielding, patient follow-up is limited with a median of 17.7 months (range: 4.2-58.9 months). Of the 56 surveyed radiation facilities in the GOG, 34 (61%) responded. One center was subsequently excluded as it performs only high dose rate brachytherapy. Of the evaluable respondents, 88% (29 out of 33) utilize a MLS in treating their patients with invasive cervical carcinoma. Of the latter group, 76% (22 out of 29), 21% (6 out of 29), and 3% (1 out of 29) employ a standard block, customized block, and a "step-wedge," respectively. For those using a standard block, 77% (17 out of 22) align the central cranial-caudal axis of the MLS along the corresponding midplane of the patient's pelvis on an anteroposterior radiograph rather than along the superior-inferior central axis of the tandem.
CONCLUSIONS: This study suggests that the use of a standard midline shield could result in potential tumor dose inhomogeneity and should be avoided. A national survey of major academic centers further suggests that the majority of these facilities also utilize a rectangular central block that is not positioned with respect to possible tandem deviation. Further investigation concerning the techniques of midline shield construction should be considered.

Entities:  

Mesh:

Year:  1997        PMID: 9054901     DOI: 10.1016/s0360-3016(96)00469-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Simultaneous integrated boost (SIB) of the parametrium and cervix in radiotherapy for uterine cervical carcinoma: a dosimetric study using a new alternative approach.

Authors:  Jen-Yu Cheng; Eng-Yen Huang; Shun-Neng Hsu; Chong-Jong Wang
Journal:  Br J Radiol       Date:  2016-10-06       Impact factor: 3.039

2.  A feasibility study of a modified treatment strategy combined external beam radiation therapy and brachytherapy for cervical cancer.

Authors:  Qi Fu; Wei Li; Jing Zuo; Xi Yang; Yingjie Xu; Manni Huang; Jusheng An; Shuangzheng Jia; Lingying Wu
Journal:  J Appl Clin Med Phys       Date:  2022-04-21       Impact factor: 2.243

3.  Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology.

Authors:  Tomoaki Tamaki; Ryuta Hirai; Mitsunobu Igari; Yu Kumazaki; Shin-Ei Noda; Yoshiyuki Suzuki; Shingo Kato
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

4.  Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario.

Authors:  Leonel Varela Cagetti; Christophe Zemmour; Eric Lambaudie; Magalie Provansal; Renaud Sabatier; Laura Sabiani; Guillaume Blache; Camille Jauffret; Marjorie Ferré; Agnès Tallet; Laurence Gonzague
Journal:  J Contemp Brachytherapy       Date:  2022-08-17

5.  Regarding the study testing the addition of gemcitabine to concurrent chemoradiotherapy in cervical carcinoma: Clarity needed.

Authors:  Swaroop Revannasiddaiah; Madhup Rastogi; Manoj Gupta; Rajeev Seam
Journal:  Indian J Med Paediatr Oncol       Date:  2013-01

6.  Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer.

Authors:  Xianliang Wang; Jie Li; Pei Wang; Ke Yuan; Gang Yin; Bin Wan
Journal:  J Contemp Brachytherapy       Date:  2016-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.